Synlogic Therapeutics develops engineered living biotherapeutics, called Synthetic Biotics, using synthetic biology to program microorganisms to address underlying drivers of disease
Synlogic Therapeutics develops engineered living biotherapeutics, called Synthetic Biotics, using synthetic biology to program microorganisms to address underlying drivers of disease. Its pipeline has focused on rare and metabolic diseases, including phenylketonuria (PKU), hyperammonemia, and maple syrup urine disease.